Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.6449
+0.00380.59%
Pre-market: 0.65220.0073+1.13%07:43 EDT
Volume:9.49M
Turnover:6.07M
Market Cap:156.71M
PE:-0.86
High:0.6586
Open:0.6500
Low:0.6191
Close:0.6411
52wk High:2.54
52wk Low:0.1611
Shares:243.00M
Float Shares:196.00M
Volume Ratio:0.86
T/O Rate:4.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-143.17%
PB:-15.08
PE(LYR):-0.36

Loading ...

Outlook Therapeutics launches best-efforts public offering of common stock and warrants

Reuters
·
Mar 24

Outlook Therapeutics Launches LYTENAVA in Germany and the UK

Reuters
·
Mar 24

Outlook Therapeutics Inc - Extends Maturity Date of Existing Convertible Note to December 31, 2026

THOMSON REUTERS
·
Mar 16

Outlook Therapeutics Inc - Enters $18.4 Mln New Note, Expects $17 Mln Net Proceeds

THOMSON REUTERS
·
Mar 16

Outlook Therapeutics Inc - Lender Confirms Existing Note Is Not in Default

THOMSON REUTERS
·
Mar 16

Outlook Therapeutics Inc - Proceeds From New Note to Pay Down Existing Note, $10.8 Mln Principal and Interest Remaining on Existing Note

THOMSON REUTERS
·
Mar 16

Press Release: Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

Dow Jones
·
Mar 16

Outlook Therapeutics director Julia A. Haller to step down effective March 10, 2026

Reuters
·
Mar 12

Outlook Therapeutics provides update following FDA meeting on ONS-5010

TIPRANKS
·
Mar 06

Outlook Therapeutics Updates on FDA Type A Meeting for ONS-5010/LYTENAVA BLA

Reuters
·
Mar 06

Outlook Therapeutics Inc - Evaluating Regulatory Options for Ons-5010/Lytenava U.S. Approval

THOMSON REUTERS
·
Mar 06

Outlook Therapeutics: to Continue Engaging in Discussions With FDA to Clarify Agency's Views on Confirmatory Evidence & Appropriate Path Forward

THOMSON REUTERS
·
Mar 06

Outlook Therapeutics Provides Update Following Type a Meeting With FDA Regarding Ons-5010/Lytenava™ (Bevacizumab-Vikg)

THOMSON REUTERS
·
Mar 06